- Home
- MFIN vs FDMT Comparison
MFIN vs FDMT Comparison
Compare MFIN & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- FDMT
- Stock Information
- Founded
- MFIN 1995
- FDMT 2013
- Country
- MFIN United States
- FDMT United States
- Employees
- MFIN N/A
- FDMT N/A
- Industry
- MFIN Finance: Consumer Services
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- MFIN Finance
- FDMT Health Care
- Exchange
- MFIN Nasdaq
- FDMT Nasdaq
- Market Cap
- MFIN 223.8M
- FDMT 192.2M
- IPO Year
- MFIN 1996
- FDMT 2020
- Fundamental
- Price
- MFIN $10.13
- FDMT $7.26
- Analyst Decision
- MFIN Strong Buy
- FDMT Buy
- Analyst Count
- MFIN 1
- FDMT 9
- Target Price
- MFIN $12.00
- FDMT $30.63
- AVG Volume (30 Days)
- MFIN 77.7K
- FDMT 2.5M
- Earning Date
- MFIN 07-30-2025
- FDMT 08-11-2025
- Dividend Yield
- MFIN 4.74%
- FDMT N/A
- EPS Growth
- MFIN N/A
- FDMT N/A
- EPS
- MFIN 1.75
- FDMT N/A
- Revenue
- MFIN $332,256,000.00
- FDMT $33,000.00
- Revenue This Year
- MFIN N/A
- FDMT $11,586.49
- Revenue Next Year
- MFIN $5.67
- FDMT N/A
- P/E Ratio
- MFIN $5.78
- FDMT N/A
- Revenue Growth
- MFIN 16.48
- FDMT N/A
- 52 Week Low
- MFIN $7.40
- FDMT $2.24
- 52 Week High
- MFIN $10.98
- FDMT $17.41
- Technical
- Relative Strength Index (RSI)
- MFIN 52.18
- FDMT 71.22
- Support Level
- MFIN $9.86
- FDMT $5.33
- Resistance Level
- MFIN $10.51
- FDMT $5.94
- Average True Range (ATR)
- MFIN 0.40
- FDMT 0.65
- MACD
- MFIN -0.02
- FDMT 0.18
- Stochastic Oscillator
- MFIN 24.11
- FDMT 91.71
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.